30 July, 2017
Evanson Asset Management Llc increased its stake in Facebook Inc (FB) by 9.86% based on its latest 2016Q4 regulatory filing with the SEC. Autus Asset Management Llc bought 14,588 shares as the company's stock rose 15.20% with the market. Capital Corp now owns 25,000 shares of the company's stock valued at $1,072,000 after buying an additional 5,000 shares during the last quarter. Finally, Saratoga Research & Investment Management boosted its stake in shares of Novo Nordisk A/S by 5.1% in the second quarter. 1,286,079 shares of the company were exchanged. About 38.32 million shares traded or 113.13% up from the average.
The share price of Novo Nordisk A/S (NYSE:NVO) was down -1.19% during the last trading session, with a day high of 41.64. It has underperformed by 16.70% the S&P500. AbbVie Inc (NYSE:ABBV) has risen 10.63% since July 27, 2016 and is uptrending.
Investors sentiment decreased to 1.25 in 2016 Q4. The dividend payment was $0.280 per share for the quarter or $1.12 on an annualized basis. It increased, as 53 investors sold DOW shares while 333 reduced holdings. 109 funds opened positions while 262 raised stakes. The investment managers in our database reported: 91.80 million shares, up from 87.70 million shares in 2016Q3. Nomura Asset Com Limited holds 0.63% or 304,252 shares in its portfolio. Mizuho Usa reported 330,000 shares stake. (NYSE:AAP). Livforsakringsbolaget Skandia Omsesidigt owns 5,364 shares or 0.05% of their U.S. portfolio. Palouse Inc owns 62,710 shares or 1.47% of their USA portfolio. Next quarter's EPS is estimated at $0.57 with next year's EPS anticipated to be $2.52.
Ledyard National Bank, which manages about $562.65 million US Long portfolio, upped its stake in Cognizant Technology Solutions (NASDAQ:CTSH) by 63,580 shares to 63,854 shares, valued at $3.58 million in 2016Q4, according to the filing. 252,486 are held by Shell Asset Mgmt. Iberiabank Corp holds 0.14% or 3,436 shares in its portfolio. Andra Ap owns 83,500 shares or 0.11% of their United States portfolio. It fall, as 47 investors sold BBT shares while 271 reduced holdings. Moreover, Ingalls & Snyder Limited Liability Company has 0.45% invested in BB&T Corporation (NYSE:BBT) for 173,939 shares. First Comml Bank accumulated 64,445 shares.
On December 6, 2016 the stock rating was changed to a "Buy" according to a UBS report which was a boost from the previous "Sell" rating. Therefore 57% are positive.
NVO has been the topic of several other reports. The firm has "Conviction Buy" rating by Goldman Sachs given on Monday, February 15. On Monday, October 19 the stock rating was upgraded by Jyske Bank to "Strong Buy". HSBC Holdings plc cut shares of Novo Nordisk A/S from a "hold" rating to a "reduce" rating in a research report on Friday, April 7th. The rating was upgraded by Zacks on Friday, August 28 to "Hold". The firm has "Buy" rating by Jefferies given on Friday, July 14.
09/01/2016 - Novo Nordisk A/S was downgraded to "equal-weight" by analysts at Morgan Stanley. Piper Jaffray initiated Novo Nordisk A S (ADR) (NYSE:NVO) on Friday, September 23 with "Neutral" rating. Therefore 32% are positive. It was reported on Jul, 28 by Barchart.com.
10/31/2016 - Novo Nordisk A/S was downgraded to "neutral" by analysts at Citigroup. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) has "Market Perform" rating given on Friday, August 28 by Leerink Swann. "The company also received approval by the FDA for the Biologics License Application (BLA) for Rebinyn for the treatment of adults and children with hemophilia B and marketing authorization in Europe for the same for the treatment of adolescents and adults with haemophilia B. Shares of Novo Nordisk have outperformed the Large Cap Pharmaceuticals industry year to date". The rating was maintained by BMO Capital Markets on Wednesday, April 19 with "Hold". CLSA maintained BB&T Corporation (NYSE:BBT) on Friday, September 23 with "Outperform" rating. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) has "Neutral" rating given on Friday, September 9 by JP Morgan. UBS downgraded Novo Nordisk A S (ADR) (NYSE:NVO) on Monday, February 8 to "Sell" rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.
